Not Yet RecruitingNot Applicable

A Single-Blind Randomized Controlled Study Comparing the Efficacy of High-Intensity Laser Therapy and Focused Extracorporeal Shock Wave Therapy in Patients With Plantar Fasciitis

28 participantsStarted 2026-02-28

Plain-language summary

This randomized controlled trial aims to evaluate the efficacy of High-Intensity Laser Therapy (HILT) and Focused Extracorporeal Shock Wave Therapy (fESWT) in reducing pain in patients with plantar fasciitis. The study also examines the effects of HILT and fESWT on health-related outcomes, including VAS-FA, FFI, plantar fascia thickness, and adverse events. Researchers will compare HILT with fESWT as treatment options for patients with plantar fasciitis. Participants will receive either HILT or fESWT along with an exercise program. They will attend follow-up visits to assess outcomes at 1, 2, 3, 6, and 12 weeks after the first treatment.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 18-70 years * Pain was worse in the initial step after and an extended period of rest * Pain was decreased initially after the first steps but exacerbated with increased activity * VAS ≥ 4 * Pain was localized and sharp but not radiating, * Pain was reproduced with palpation of the plantar fascia Exclusion Criteria: * Have Wound/Infection/tumor in treatment area * History of foot trauma in 3 months * History of intervention at plantar fascia in 6 months such as Ultrasound therapy, steroid injection, surgery or botulinum toxin injection * Pain medication within one week before participation * Patient wasn't desired to participate in the study

What they're measuring

Visual analog scale (VAS)

Timeframe: Pre-treatment, and at 1-, 2-, 3-, 6-, and 12-week post-treatment

Trial details

NCT IDNCT07287046

SponsorMahidol University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-25

Contact for this trial

Peerada Eurcherdkul, Doctor of Medicine

+6692-272-0652 eurpeerada@gmail.com